Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries

Prymula, Roman; Povey, Michael; Brzostek, Jerzy; Cabrnochova, Hana; Chlíbek, Roman; Czajka, Hanna; Levinienė, Giedra; Man, Sorin Claudiu; Neamtu, ML; Pazdiora, P; Pleșca, Doina Anca; Růžková, Renata; Štefkovičová, Mária; Usonis, Vytautas; Verdanova, Daniela; Wysocki, Jacek; Casabona, G.; Habib, Ahsan

doi:10.1016/j.vaccine.2021.03.085

Cited by 10 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35 The trivalent MMR vaccine effectively modulates durable immunity against measles, mumps, and rubella, making it one of the most successful human vaccines to date. [45][46][47][48][49][50] Numerous preclinical and clinical studies have demonstrated the high immunogenicity and antitumor efficacy of vaccine lineages of measles and mumps. [38][39][40][41] Based upon extensive data on the immunomodulatory properties of MMR, we evaluate the antitumor potential of its IT administrations in two preclinical mouse models.…”

Section: Discussionmentioning

confidence: 99%

“…Based on the abundant clinical evidence of the immunomodulatory properties of MMR, [45][46][47][48][49][50] we hypothesize that its IT administrations can elicit an antitumor immune response. To investigate this, we subcutaneously implanted mouse HCC (Hepa 1-6) or CRC (MC38) cells into the right flanks of immune-competent mice.…”

Section: It Injections Of Mmr Induce Subcutaneous Tumor Growth Inhibi...mentioning

confidence: 99%

“…MMR has been shown to stimulate a potent and longlasting protective immunity against measles, mumps, and rubella in humans. [45][46][47][48][49][50] And multiple studies have also demonstrated that vaccine lineages of measles and mumps viruses are effective against human tumors in cell culture, animal models, and clinical trials. 38,40,41,51,52 Furthermore, MMR is readily available, low-cost, and accessible worldwide, and its use requires no regulatory approval from the US Food and Drug Administration (FDA).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy

Nagalo¹,

Zhang

Taylor

et al. 2022

Preprint

View full text Add to dashboard Cite

Despite its rising promise, cancer immunotherapy remains out of reach for many patients because of the extensive cost of manufacturing immunotherapy products. In this study, we show that intratumoral injections of the trivalent measles, mumps, and rubella (MMR) live attenuated viral vaccine (LAVs) modulates a potent cytotoxic T-cell antitumor immune response, resulting in tumor growth inhibition and improved survival in syngeneic mouse models of hepatocellular carcinoma and colorectal cancer. Using an integrated transcriptomic and proteomic approach, we demonstrated that mechanistically, MMR exerts its antitumor activity by priming innate and adaptive antitumor immune responses, leading to immunologically coordinated cancer cells death. Our findings highlight a promising potential for LAVs, such as MMR, to be repurposed as cost-effective cancer immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: It Injections Of Mmr Induce Subcutaneous Tumor Growth Inhibi...mentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy

Nagalo¹,

Zhang

Taylor

et al. 2022

Preprint

View full text Add to dashboard Cite

show abstract

“…The demographic characteristics of the study participants were reported previously. 11,12,31 The participant population was overall homogeneous and comparable between countries in terms of mean age, gender distribution, and ethnicity (Supplementary Table S1). Most participants were recruited in the Czech Republic, Russia, and Poland (Table 1).…”

Section: Demographic Characteristicsmentioning

confidence: 99%

Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries

Gillard

Povey

Carryn

2021

Human Vaccines & Immunotherapeutics

Self Cite

View full text Add to dashboard Cite

show abstract

“…The trivalent live attenuated measles, mumps, and rubella viruses (MMR) vaccine is attractive as an immunovirotherapy primarily for its proven safety record but has other useful features as well. MMR has been shown to stimulate a potent and long-lasting protective immunity against measles, mumps, and rubella in humans (30)(31)(32)(33)(34)(35). Moreover, studies have shown that vaccine lineages of measles and mumps viruses exert effective cytotoxicity against human tumors in cell cultures, animal models, and clinical trials (24,26,27,36,37).…”

Section: Introductionmentioning

confidence: 99%

Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy

et al. 2022

View full text Add to dashboard Cite

It has long been known that oncolytic viruses wield their therapeutic capability by priming an inflammatory state within the tumor and activating the tumor immune microenvironment, resulting in a multifaceted antitumor immune response. Vaccine-derived viruses, such as measles and mumps, have demonstrated promising potential for treating human cancer in animal models and clinical trials. However, the extensive cost of manufacturing current oncolytic viral products makes them far out of reach for most patients. Here by analyzing the impact of intratumoral (IT) administrations of the trivalent live attenuated measles, mumps, and rubella viruses (MMR) vaccine, we unveil the cellular and molecular basis of MMR-induced anti-cancer activity. Strikingly, we found that IT delivery of low doses of MMR correlates with tumor control and improved survival in murine hepatocellular cancer and colorectal cancer models via increased tumor infiltration of CD8+ granzyme B+ T-cells and decreased macrophages. Moreover, our data indicate that MMR activates key cellular effectors of the host’s innate and adaptive antitumor immunity, culminating in an immunologically coordinated cancer cell death. These findings warrant further work on the potential for MMR to be repurposed as safe and cost-effective cancer immunotherapy to impact cancer patients globally.

show abstract

Ten-year follow-up on efficacy, immunogenicity and safety of two doses of a combined measles-mumps-rubella-varicella vaccine or one dose of monovalent varicella vaccine: Results from five East European countries

Cited by 10 publications

References 25 publications

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy

Repurposing Live Attenuated Trivalent MMR Vaccine as Cost-effective Cancer Immunotherapy

Clinically- versus serologically-identified varicella: A hidden infection burden. A ten-year follow-up from a randomized study in varicella-endemic countries

Repurposing live attenuated trivalent MMR vaccine as cost-effective cancer immunotherapy

Contact Info

Product

Resources

About